{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:51:07Z","timestamp":1781877067453,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04146-y","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:36:12Z","timestamp":1770107772000},"page":"2518-2522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic insights into HAGLROS-mediated therapy resistance in ovarian cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Mohadeseh","family":"Sheykhi-Sabzehpoush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Abedzeydi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Khombi","family":"Shooshtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Cheraghzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Moramezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Khavanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6239-8745","authenticated-orcid":false,"given":"Maryam","family":"Farzaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"4","key":"4146_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367\u2013401.","journal-title":"Genes Dis"},{"key":"4146_CR2","doi-asserted-by":"publisher","first-page":"1393852","DOI":"10.3389\/fimmu.2024.1393852","volume":"15","author":"Y Shen","year":"2024","unstructured":"Shen Y, et al. Independent organelle and organelle\u2014organelle interactions: essential mechanisms for malignant gynecological cancer cell survival. Front Immunol. 2024;15:1393852.","journal-title":"Front Immunol"},{"issue":"3","key":"4146_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4146_CR4","doi-asserted-by":"publisher","DOI":"10.2174\/0115665240345216241120093846","author":"MAG Dari","year":"2025","unstructured":"Dari MAG, et al. miR-34 as a critical regulator in ovarian cancer. Curr Mol Med. 2025. https:\/\/doi.org\/10.2174\/0115665240345216241120093846.","journal-title":"Curr Mol Med"},{"issue":"4","key":"4146_CR5","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4146_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9\u201332.","journal-title":"Cancer Biol Med"},{"key":"4146_CR7","doi-asserted-by":"crossref","unstructured":"Ahmed HG, Fatima T, Khaliq N. Non-coding RNA-Mediated regulation of genes expression in response to abiotic stresses. ncRNAs: Med Regul Unargua Biol Funct Environ Constr, 2024: p. 235\u2013264.","DOI":"10.1007\/978-3-031-69354-0_9"},{"issue":"8","key":"4146_CR8","first-page":"855","volume":"16","author":"ME Dashtaki","year":"2023","unstructured":"Dashtaki ME, Ghasemi S. Anti-angiogenic drug resistance: roles and targeting of non-coding RNAs (microRNAs and long non-coding RNAs). Curr Mol Pharmacol. 2023;16(8):855\u201369.","journal-title":"Curr Mol Pharmacol"},{"key":"4146_CR9","doi-asserted-by":"publisher","DOI":"10.2174\/0115665240339328241217184041","author":"O Anbiyaee","year":"2025","unstructured":"Anbiyaee O, et al. LncRNA-DANCR: a key player in colorectal cancer development and progression. Curr Mol Med. 2025. https:\/\/doi.org\/10.2174\/0115665240339328241217184041.","journal-title":"Curr Mol Med"},{"key":"4146_CR10","doi-asserted-by":"publisher","first-page":"1417306","DOI":"10.3389\/fmolb.2024.1417306","volume":"11","author":"R Wang","year":"2024","unstructured":"Wang R, et al. Recent progress of exosomal lncRNA\/circRNA\u2013miRNA\u2013mRNA axis in lung cancer: implication for clinical application. Front Mol Biosci. 2024;11:1417306.","journal-title":"Front Mol Biosci"},{"issue":"19","key":"4146_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18590","volume":"28","author":"J Xie","year":"2024","unstructured":"Xie J, et al. LncRNA\u2013miRNA interactions prediction based on meta-path similarity and Gaussian kernel similarity. J Cell Mol Med. 2024;28(19):e18590.","journal-title":"J Cell Mol Med"},{"key":"4146_CR12","doi-asserted-by":"publisher","first-page":"1621144","DOI":"10.3389\/or.2025.1621144","volume":"19","author":"V Barbi","year":"2025","unstructured":"Barbi V, et al. Non-coding RNAs as novel biomarkers and therapeutic targets in breast cancer. Oncol Rev. 2025;19:1621144.","journal-title":"Oncol Rev"},{"key":"4146_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102982","volume":"134","author":"D Kumar","year":"2023","unstructured":"Kumar D, et al. Non-coding RNAs in immunoregulation and autoimmunity: technological advances and critical limitations. J Autoimmun. 2023;134:102982.","journal-title":"J Autoimmun"},{"key":"4146_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.649619","author":"A Chowdhary","year":"2021","unstructured":"Chowdhary A, Satagopam V, Schneider R. Long non-coding RNAs: mechanisms, experimental, and computational approaches in identification, characterization, and their biomarker potential in cancer. Front Genet. 2021. https:\/\/doi.org\/10.3389\/fgene.2021.649619.","journal-title":"Front Genet"},{"issue":"8","key":"4146_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41419-024-07020-x","volume":"15","author":"Z Meng","year":"2024","unstructured":"Meng Z, et al. LncRNA HAGLROS promotes breast cancer evolution through miR-135b-3p\/COL10A1 axis and exosome-mediated macrophage M2 polarization. Cell Death Dis. 2024;15(8):633.","journal-title":"Cell Death Dis"},{"issue":"3","key":"4146_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4048\/jbc.2021.24.e24","volume":"24","author":"C Zhang","year":"2021","unstructured":"Zhang C, et al. HOXD antisense growth-associated long noncoding RNA promotes triple-negative breast cancer progression by activating Wnt signaling pathway. J Breast Cancer. 2021;24(3):315\u201329.","journal-title":"J Breast Cancer"},{"issue":"4","key":"4146_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/0113894501345632241022055444","volume":"26","author":"J Yang","year":"2024","unstructured":"Yang J, et al. LncRNA HAGLROS: a vital oncogenic propellant in various human cancers. Curr Drug Targets. 2024;26(4):267\u201381.","journal-title":"Curr Drug Targets"},{"issue":"4","key":"4146_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317697574","volume":"39","author":"C Lu","year":"2017","unstructured":"Lu C, Ma J, Cai D. Increased HAGLR expression promotes non\u2013small cell lung cancer proliferation and invasion via enhanced de novo lipogenesis. Tumor Biol. 2017;39(4):1010428317697574.","journal-title":"Tumor Biol"},{"issue":"9","key":"4146_CR19","doi-asserted-by":"publisher","first-page":"10490","DOI":"10.1096\/fj.201802543RR","volume":"33","author":"C Yang","year":"2019","unstructured":"Yang C, et al. Long noncoding RNA HAGLR acts as a microRNA-143-5p sponge to regulate epithelial-mesenchymal transition and metastatic potential in esophageal cancer by regulating LAMP3. FASEB J. 2019;33(9):10490\u2013504.","journal-title":"FASEB J"},{"issue":"1","key":"4146_CR20","doi-asserted-by":"publisher","first-page":"111461","DOI":"10.1016\/j.yexcr.2019.06.006","volume":"382","author":"X Guo","year":"2019","unstructured":"Guo X, et al. Long non-coding RNA-HAGLR suppressed tumor growth of lung adenocarcinoma through epigenetically silencing E2F1. Exp Cell Res. 2019;382(1):111461.","journal-title":"Exp Cell Res"},{"key":"4146_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.876090","author":"S Xiao","year":"2022","unstructured":"Xiao S, et al. Long noncoding RNA HAGLROS promotes the malignant progression of bladder cancer by regulating the miR-330-5p\/SPRR1B axis. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.876090.","journal-title":"Front Oncol"},{"key":"4146_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0756-y","volume":"17","author":"J-F Chen","year":"2018","unstructured":"Chen J-F, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018;17:1\u201316.","journal-title":"Mol Cancer"},{"key":"4146_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00404-019-05218-5","volume":"300","author":"M Yang","year":"2019","unstructured":"Yang M, et al. Clinical significance and oncogene function of long noncoding RNA HAGLROS overexpression in ovarian cancer. Arch Gynecol Obstet. 2019;300:703\u201310.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"4146_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12943-017-0756-y","volume":"17","author":"JF Chen","year":"2018","unstructured":"Chen JF, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018;17(1):6.","journal-title":"Mol Cancer"},{"key":"4146_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.intimp.2019.04.049","volume":"73","author":"H Wei","year":"2019","unstructured":"Wei H, et al. Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095\/ATG12 axis in hepatocellular carcinoma cells. Int Immunopharmacol. 2019;73:72\u201380.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"4146_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10311","volume":"22","author":"L Zhu","year":"2021","unstructured":"Zhu L, Mei M. Interference of long non-coding RNA HAGLROS inhibits the proliferation and promotes the apoptosis of ovarian cancer cells by targeting miR-26b-5p. Exp Ther Med. 2021;22(2):1\u20138.","journal-title":"Exp Ther Med"},{"key":"4146_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.947332","volume":"12","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Regulation of autophagy by non-coding RNAs in gastric cancer. Front Oncol. 2022;12:947332.","journal-title":"Front Oncol"},{"issue":"1","key":"4146_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"31","key":"4146_CR29","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"PM LoRusso","year":"2016","unstructured":"LoRusso PM. Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803\u201315.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4146_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3892\/etm.2021.10311","volume":"22","author":"L Zhu","year":"2021","unstructured":"Zhu L, Mei M. Interference of long non-coding RNA HAGLROS inhibits the proliferation and promotes the apoptosis of ovarian cancer cells by targeting miR-26b-5p. Exp Ther Med. 2021;22(2):879.","journal-title":"Exp Ther Med"},{"key":"4146_CR31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13080","author":"L Zhan","year":"2016","unstructured":"Zhan L, et al. Autophagy as an emerging therapy target for ovarian carcinoma. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.13080.","journal-title":"Oncotarget"},{"issue":"2","key":"4146_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/15548627.2015.1009781","volume":"11","author":"J He","year":"2015","unstructured":"He J, et al. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy. 2015;11(2):373\u201384.","journal-title":"Autophagy"},{"issue":"3","key":"4146_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00404-019-05218-5","volume":"300","author":"M Yang","year":"2019","unstructured":"Yang M, et al. Clinical significance and oncogene function of long noncoding RNA HAGLROS overexpression in ovarian cancer. Arch Gynecol Obstet. 2019;300(3):703\u201310.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"4146_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8(1):375.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4146_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24168","volume":"36","author":"L Shu","year":"2022","unstructured":"Shu L, et al. Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100. J Clin Lab Anal. 2022;36(1):e24168.","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"4146_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/jop.13249","volume":"51","author":"Y Ma","year":"2022","unstructured":"Ma Y, et al. HAGLROS promotes cell proliferation and angiogenesis and inhibits apoptosis by activating multiple signaling pathways in LSCC cells. J Oral Pathol Med. 2022;51(6):510\u20139.","journal-title":"J Oral Pathol Med"},{"issue":"3","key":"4146_CR37","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1080\/21655979.2022.2049472","volume":"13","author":"G Tang","year":"2022","unstructured":"Tang G, et al. Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin \u03b12 (KPNA2) and inactivate p53 signaling. Bioengineered. 2022;13(3):7829\u201346.","journal-title":"Bioengineered"},{"key":"4146_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-0680-3_1","volume":"2161","author":"L Stojic","year":"2020","unstructured":"Stojic L. Tuning the expression of long noncoding RNA loci with CRISPR interference. Methods Mol Biol. 2020;2161:1\u201316.","journal-title":"Methods Mol Biol"},{"issue":"12","key":"4146_CR39","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.3390\/cancers12123695","volume":"12","author":"KM Lucere","year":"2020","unstructured":"Lucere KM, O\u2019Malley MMR, Diermeier SD. Functional screening techniques to identify long non-coding rnas as therapeutic targets in cancer. Cancers (Basel). 2020;12(12):3695.","journal-title":"Cancers (Basel)"},{"issue":"24","key":"4146_CR40","doi-asserted-by":"publisher","first-page":"17163","DOI":"10.1074\/jbc.M114.558288","volume":"289","author":"J Wang","year":"2014","unstructured":"Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 2014;289(24):17163\u201373.","journal-title":"J Biol Chem"},{"issue":"1","key":"4146_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10(1):31.","journal-title":"Cell Biosci"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04146-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04146-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04146-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:57Z","timestamp":1781873877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04146-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4146"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04146-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}